A study published Sunday by the journal Phytomedicine reports that the cannabis compound cannabidiol (CBD) demonstrated strong anti-tumor activity against melanoma by activating an epigenetic pathway that promotes cancer cell death and limits metastasis. The research was conducted by scientists from Kunming Medical University and the National University of Defense Technology.
Melanoma remains one of the most aggressive skin cancers, with advanced stages often resistant to chemotherapy and associated with significant toxicity, notes the study’s researchers, who say they set out to determine whether CBD, the non-intoxicating compound derived from marijuana, could offer a safer therapeutic approach while also clarifying how it works at a molecular level.
According to the study’s abstract, “CBD significantly induced apoptosis and inhibited cell proliferation and invasion of melanoma cells in vitro, while reducing pulmonary metastasis in vivo.” Using human melanoma cell lines and a mouse lung-metastasis model, the team found that CBD not only slowed tumor growth but also reduced the spread of cancer to the lungs.
A central finding of the study was the identification of peroxisome proliferator-activated receptor gamma (PPARγ) as a key mediator of CBD’s anti-cancer effects. Through pharmacological analysis, molecular docking, and protein-level validation, the researchers determined that CBD activates PPARγ, a nuclear receptor already known to regulate cell survival and tumor progression.
Beyond direct tumor suppression, the research uncovered an epigenetic mechanism underlying CBD’s effects. Transcriptomic and genome-wide methylation analyses showed that CBD altered global DNA methylation patterns through formation of a PPARγ–TET1 complex. This interaction led to demethylation and activation of LRSAM1, a gene newly identified by the authors as having anti-cancer properties. The abstract notes that upregulation of LRSAM1 “markedly enhanced melanoma cell apoptosis and suppressed proliferation.”
The authors concluded that “CBD exhibited strong antitumor activity in melanoma by modulating the PPARγ–TET1 complex to induce demethylation of LRSAM1, thereby suppressing tumor progression.” They described this as “the first evidence that CBD inhibits melanoma progression by modulating gene methylation”.
While the findings are preclinical, the study positions CBD as a promising therapeutic candidate for melanoma and highlights epigenetic regulation as a potential target for future treatment development.
More articles from The Marijuana Herald can be found below.
